Elicio Therapeutics (ELTX) Assets (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Assets came in at $22.7 million in Q1 2026, down 19.48% YoY from $28.2 million in Q1 2025, and down 12.27% on a QoQ basis from $25.9 million in Q4 2025.
Elicio Therapeutics (ELTX) Assets (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Assets data on file, last reported at $22.7 million in Q1 2026.
- Quarterly Assets fell 19.48% year-over-year to $22.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.7 million (down 19.48% YoY) and the FY2025 annual result came in at $25.9 million, down 8.22% from the prior year.
- Assets slipped to $22.7 million in Q1 2026, from $25.9 million in the prior quarter.
- In the past five years, Assets ranged from a high of $81.3 million in Q1 2022 to a low of $15.8 million in Q2 2024.
- A 5-year average of $36.2 million and a median of $28.3 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets sank 76.52% — and 2025, when it surged 87.48%.
- Tracing ELTX's Assets over 5 years: stood at $22.7 million in 2022, then grew by 19.78% to $27.1 million in 2023, then gained by 3.8% to $28.2 million in 2024, then slipped by 8.22% to $25.9 million in 2025, then slipped by 12.27% to $22.7 million in 2026.
- The last three Assets figures came in at $22.7 million (Q1 2026), $25.9 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 31.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.33 Mn |
| Mar 31, 2026 | 22.69 Mn |
| Dec 31, 2025 | 25.86 Mn |
| Sep 30, 2025 | 28.28 Mn |
| Jun 30, 2025 | 29.53 Mn |
| Mar 31, 2025 | 28.18 Mn |
| Dec 31, 2024 | 28.18 Mn |
| Sep 30, 2024 | 38.39 Mn |
| Jun 30, 2024 | 15.75 Mn |
| Mar 31, 2024 | 24.48 Mn |
| Dec 31, 2023 | 27.15 Mn |
| Sep 30, 2023 | 30.99 Mn |
| Jun 30, 2023 | 37.62 Mn |
| Mar 31, 2023 | 41.77 Mn |
| Dec 31, 2022 | 22.66 Mn |
| Sep 30, 2022 | 61.32 Mn |
| Jun 30, 2022 | 70.81 Mn |
| Mar 31, 2022 | 81.26 Mn |
| Dec 31, 2021 | 96.51 Mn |
| Sep 30, 2021 | 109.94 Mn |